Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Quarterly Financial Results and Performance
IBRX logo

ImmunityBio Reports 434% Surge in ANKTIVA Revenue Amid Rapid Commercial Expansion

IBRX10-QFiling Date: 11/5/2025
ImmunityBio, Inc.
Description

What this story covers

ImmunityBio’s Q3 2025 filing reveals explosive 434% revenue growth driven by ANKTIVA’s successful launch. While managing a $3.7 billion deficit and significant debt, the company is aggressively expanding its oncology pipeline and scaling international operations.

Story snapshot

CompanyImmunityBio, Inc.
TickerIBRX
VariantStandard detailed
Duration12:58
Filing type10-Q
PeriodQ3 2025
IndustryHealthcare & Pharmaceuticals
Accession0001326110-25-000139
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing10-QView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in